For a patient with an otherwise stage III NSCLC with some limited CNS involvement, under what circumstances would you consider offering definitive chemoradiation plus SRS?

Community
Company
News
Contact Us
Sign in

Topics: Lung Cancer • Thoracic Malignancies • Medical Oncology • NCI-CCC Tumor Board Question • Vanderbilt • NCI-CCC Thoracic Tumor Board Question

Would you offer this approach to a patient with 3 subcentimeter CNS metastases?

Related Questions

In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?

In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?

Would you add ALK-targeted therapy for patients with EGFR L858R-mutant lung adenocarcinoma who progress on targeted therapy and develop a concomitant STRN-ALK fusion?

Do you prefer cisplatin or carboplatin in combination with nivolumab per CheckMate 816 for patients with resectable NSCLC?

For patients with metastatic thymic carcinoma, is there a role for local treatment options such as SBRT for oligoprogressive or oligopersistent disease after systemic therapy?

Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?

What are your top takeaways in Thoracic Cancers from ASCO 2023?

How would you manage a left sided triple negative breast cancer with a concurrent left sided locally advanced non-small cell lung cancer?

What is your approach for an RA patient with lung cancer who is starting immunotherapy?

Is dyspnea without radiation pneumonitis a side effect of lung radiation?